Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment

Mucosal Immunol. 2022 Jan;15(1):10-26. doi: 10.1038/s41385-021-00433-3. Epub 2021 Jul 27.

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are both characterized by chronic inflammation and severe dysfunction of the gastrointestinal tract. These two forms of inflammatory bowel disease (IBD) represent distinct clinical disorders with diverse driving mechanisms; however, this divergence is not reflected in currently approved therapeutics that commonly target general proinflammatory pathways. A compelling need therefore remains to understand factors that differentiate the topology and the distinct clinical manifestations of CD versus UC, in order to develop more effective and specialized therapies. Animal models provide valuable platforms for studying IBD heterogeneity and deciphering disease-specific mechanisms. Both the established and the newly developed ileitis mouse models are characterized by various disease initiating mechanisms and diverse phenotypic outcomes that reflect the complexity of human CD-ileitis. Microbial dysbiosis, destruction of epithelial barrier integrity, immune cell deregulation, as well as the recently described genome instability and stromal cell activation have all been proposed as the triggering factors for the development of ileitis-associated pathology. In this review, we aim to critically evaluate the mechanistic underpinnings of murine models of CD-ileitis, discuss their phenotypic similarities to human disease, and envisage their further exploitation for the development of novel targeted and personalized therapeutics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Crohn Disease / physiopathology*
  • Crohn Disease / therapy
  • Disease Models, Animal
  • Dysbiosis / physiopathology*
  • Dysbiosis / therapy
  • Humans
  • Ileitis / physiopathology*
  • Ileitis / therapy
  • Inflammation
  • Mice
  • Phenotype